Panbela Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.panbela.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
- Conditions
- Pancreatic Ductal AdenocarcinomaPancreatic Cancer MetastaticPancreatic Cancer Stage IV
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05254171
- Locations
- 🇺🇸
Genesis Cancer and Blood Institute (SCRI), Hot Springs, Arkansas, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
- Conditions
- Pancreatic Cancer MetastaticPancreatic Cancer Stage IVStage IV Pancreatic Cancer
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03412799
- Locations
- 🇺🇸
Scripps MD Anderson Cancer Center, La Jolla, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Study of SBP-101 in Pancreatic Cancer
- Conditions
- Pancreatic CancerDuctal Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02657330
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇦🇺Ashford Cancer Centre, Kurralta Park, South Australia, Australia
News
Panbela Therapeutics Secures $12 Million Investment and Advances Clinical Programs
Panbela Therapeutics secured a $12 million financing commitment from Nant Capital to advance its clinical programs.
Panbela Therapeutics Initiates Phase I Trial of CPP-1X-S in STK11 Mutant NSCLC
Panbela Therapeutics has dosed the first patient in a Phase I trial evaluating CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC).